Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Patrys Limited ( (AU:PAB) ) is now available.
Patrys Limited has announced that all seven resolutions put to shareholders at its General Meeting in Perth on 19 January 2026 were passed by poll, enabling the company to proceed with a series of equity and equity‑linked issuances. The approvals cover the issue of consideration shares, performance rights, convertible notes and their associated conversion shares, vendor facilitation shares, incentive options for a director, and shares for facilitators and corporate advisers, collectively reinforcing the company’s capacity to fund transactions and incentives tied to its strategic and capital management plans.
More about Patrys Limited
Patrys Limited (ASX:PAB) is a biotechnology company focused on developing its deoxymab platform of cell‑penetrating antibodies as therapeutic candidates for a range of medical indications. The company aims to leverage this proprietary antibody technology to create novel treatments, positioning itself within the innovative biologics and antibody‑based therapy segment of the life sciences sector.
Average Trading Volume: 622,959
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$9.54M
For an in-depth examination of PAB stock, go to TipRanks’ Overview page.